[go: up one dir, main page]

AU2001211213A1 - Stable oral formulation containing benzimidazole derivative - Google Patents

Stable oral formulation containing benzimidazole derivative

Info

Publication number
AU2001211213A1
AU2001211213A1 AU2001211213A AU1121301A AU2001211213A1 AU 2001211213 A1 AU2001211213 A1 AU 2001211213A1 AU 2001211213 A AU2001211213 A AU 2001211213A AU 1121301 A AU1121301 A AU 1121301A AU 2001211213 A1 AU2001211213 A1 AU 2001211213A1
Authority
AU
Australia
Prior art keywords
formulation containing
oral formulation
benzimidazole derivative
stable oral
containing benzimidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU2001211213A
Inventor
Philippe Baudier
Antonio Sereno
Francis Vanderbist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galephar MF
Original Assignee
Galephar MF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar MF filed Critical Galephar MF
Publication of AU2001211213A1 publication Critical patent/AU2001211213A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

An enteric formulation containing at least one benzimidazole compound, said formulation containing: a core containing at least one benzimidazole compound and at least one lipophilic antioxidant, and an enteric envelope protecting the core at least at a pH of 3 to 5, preferably at a pH of 1 to 5.
AU2001211213A 2000-10-20 2000-10-20 Stable oral formulation containing benzimidazole derivative Withdrawn AU2001211213A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BE2000/000126 WO2002032427A1 (en) 2000-10-20 2000-10-20 Stable oral formulation containing benzimidazole derivative

Publications (1)

Publication Number Publication Date
AU2001211213A1 true AU2001211213A1 (en) 2002-04-29

Family

ID=3862554

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2001211213A Withdrawn AU2001211213A1 (en) 2000-10-20 2000-10-20 Stable oral formulation containing benzimidazole derivative
AU2002210284A Expired AU2002210284B2 (en) 2000-10-20 2001-10-18 Stable oral formulation containing benzimidazole derivative
AU1028402A Pending AU1028402A (en) 2000-10-20 2001-10-18 Stable oral formulation containing benzimidazole derivative

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2002210284A Expired AU2002210284B2 (en) 2000-10-20 2001-10-18 Stable oral formulation containing benzimidazole derivative
AU1028402A Pending AU1028402A (en) 2000-10-20 2001-10-18 Stable oral formulation containing benzimidazole derivative

Country Status (8)

Country Link
US (3) US20040043069A1 (en)
EP (1) EP1326609B1 (en)
AT (1) ATE302004T1 (en)
AU (3) AU2001211213A1 (en)
CA (1) CA2426175A1 (en)
DE (1) DE60112781T2 (en)
DK (1) DK1326609T3 (en)
WO (2) WO2002032427A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
WO2004062552A2 (en) * 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
GB0606212D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Pharmaceutical compositions
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
EP3158991B1 (en) * 2010-01-28 2021-03-17 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2544723A2 (en) * 2010-03-10 2013-01-16 Giuliani International Limited Compositions for colon lavage and methods of making and using same
ES2718902T3 (en) 2012-03-20 2019-07-05 Eagle Pharmaceuticals Inc Liquid composition intended to be used in a method of treating conditions in response to bendamustine in patients requiring reduced volumes for administration
HUE064884T2 (en) 2012-03-20 2024-04-28 Eagle Pharmaceuticals Inc Formulations of bendamustine
JO3464B1 (en) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd Compositions of Tiacumicin Compounds
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN113384547B (en) * 2021-06-25 2024-03-19 上海信谊万象药业股份有限公司 Omeprazole aluminum magnesium carbonate composite tablet and preparation process thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19918434A1 (en) * 1999-04-23 2000-10-26 Basf Ag Storage-stable solid proton pump inhibitor formulation useful e.g. for treating duodenal ulcers, comprises amorphous active agent embedded in auxiliary matrix
US6262085B1 (en) * 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same

Also Published As

Publication number Publication date
CA2426175A1 (en) 2002-04-25
US20070196486A1 (en) 2007-08-23
WO2002032427A1 (en) 2002-04-25
EP1326609B1 (en) 2005-08-17
DK1326609T3 (en) 2006-01-02
DE60112781D1 (en) 2005-09-22
DE60112781T2 (en) 2006-05-18
US20040043069A1 (en) 2004-03-04
WO2002032425A2 (en) 2002-04-25
EP1326609A2 (en) 2003-07-16
ATE302004T1 (en) 2005-09-15
WO2002032425A3 (en) 2003-01-16
AU1028402A (en) 2002-04-29
US20080311204A1 (en) 2008-12-18
AU2002210284B2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
AU2001211213A1 (en) Stable oral formulation containing benzimidazole derivative
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
AU2002243277A1 (en) Methods and compositions for encapsulating active agents
ATE190834T1 (en) ORAL COMPOSITION AGAINST PLAQUE
AU2001290257A2 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2001290257A1 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
AU2001294606A1 (en) Substituted azepino(4,5b)indoline derivatives
EP1193270A3 (en) Pyrrolobenzodiazepines
AU2001279202A1 (en) Compositions containing phosphate and xanthan gum variants
PL341054A1 (en) Novel suppositiories containing an active compound being unstable in acid environments
AU2277101A (en) Stable extended release oral dosage composition
IL142063A0 (en) Tetrahydropyridoether derivatives and pharmaceutical compositions containing the same
AU2001292185A1 (en) Formulation containing amoxicillin
AU2001265111A1 (en) Benzenedicarboxylic acid derivatives
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
AP2003002716A0 (en) Medicinal compositions containing propenone derivatives.
GEP20063972B (en) Streptogramin derivatives, preparation and compositions containing them
AU2001226794A1 (en) Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
IL137794A0 (en) Streptogramin derivatives, preparation method and compositions containing same
AU4317500A (en) Antibiral compositions containing phorbol derivatives as the main active ingredient
AU2001274182A1 (en) Antiplaque aqueous oral composition
WO2001024803A3 (en) Pharmaceutical compositions containing copper, salicylic acid and vitamines c
ATE305291T1 (en) ORAL COMPOSITION CONTAINING 2'-HYDROXYPROPIOPHENONE
AU4784900A (en) Polyolefin compositions using natural compound as antioxidant and/or heat-resistant
AU2001290291A1 (en) Cellulosic composition containing lignophenol derivative